It begins with an unexpected idea — that some of the most powerful cancer-fighting tools might already exist in our medicine cabinets. The speakers describe “repurposed drugs,” old medications originally designed for other illnesses that, decades later, are revealing surprising new potential against cancer. These drugs, they explain, are safe, inexpensive, and globally available — yet largely overlooked by mainstream oncology.
Ivermectin, a simple antiparasitic once known for saving millions from river blindness, becomes the centerpiece of discussion. Researchers first revisited it during the COVID-19 pandemic, but soon stumbled upon a forgotten treasure trove of studies suggesting it might also interfere with cancer growth. Laboratory data showed that Ivermectin could disrupt cancer cell metabolism, starve tumors by cutting off their blood supply, and even block enzymes that enable cancer to spread. Though these findings are mostly preclinical, they sparked growing interest in formal human trials.
The conversation then widens to other antiparasitic drugs — fenbendazole and mebendazole — both showing remarkable results in lab studies and occasional real-world cases. Mebendazole, already FDA-approved as a dewormer for humans, has drawn particular scientific attention for its safety and early success in cancer trials. Fenbendazole, a veterinary medicine, burst into the spotlight after Joe Tippens publicly credited it for his stunning recovery from terminal lung cancer. His story prompted more investigation, including published reports from Stanford University documenting patients who experienced similar turnarounds.
As the dialogue deepens, the speakers confront a troubling phenomenon they call “turbo cancers” — aggressive, fast-moving malignancies that sometimes emerge or return without warning. Against this backdrop, they recount numerous stories of patients who turned to Ivermectin, fenbendazole, or mebendazole — often alongside chemotherapy — and witnessed surprising outcomes: tumor shrinkage, disease stabilization, or even remission.
Yet beneath the optimism runs frustration. The speakers argue passionately for every patient’s right to try alternative or repurposed treatments, especially when conventional medicine has reached its limits. They criticize rigid oncology protocols that dismiss nonstandard therapies and urge compassion for those seeking hope beyond the textbook.
Toward the end, the discussion turns practical. Some patients, they note, combine these drugs with chemotherapy and report not only stronger tumor responses but fewer side effects — though many conceal their regimens from doctors out of fear of being rejected or scolded. They outline safety data showing that fenbendazole and mebendazole can occasionally raise liver enzymes but are otherwise well-tolerated. Careful, personalized dosing — alternating drugs or adjusting amounts — seems to further reduce risk.
In closing, the speakers remind listeners that healing often requires more than one tool. They highlight simple, often-neglected measures — such as maintaining optimal vitamin D levels — which can strengthen the body’s defenses and may play a quiet but crucial role in cancer prevention and recovery.
The story they tell is both scientific and deeply human: a call for open-minded exploration, patient empowerment, and the belief that answers might lie in the most unexpected places.
Source from: Repurposed drug — Dr. William Makis MD. Radiologist, Oncologist, Cancer Researcher, Author of 100+ publications. Youtube Channel /3.26M subscribers